New Hope Vitality to Celebrate Grand Opening of Wellness Clinic in Costa Mesa
New IV Therapy & Wellness Clinic Offers Modern Treatments for Energy, Immunity, and Mental Health
New Hope Vitality, formerly known as Oceans IV Hydration of Costa Mesa, is excited to announce the Grand Opening of its new wellness clinic on Saturday, June 14, 2025, from 10:00 a.m. to 3:00 p.m. The clinic is located at 1503 S Coast Dr, Suite 313, near Harbor Boulevard and the 405 freeway. New Hope Vitality provides a wide range of modern wellness treatments, including IV hydration therapy, vitamin infusions, and non-invasive mental health services. Treatments are available in-clinic, with select services offered throughout all of Orange County via mobile care.
Grand Opening Celebration
The Grand Opening event invites the local community to explore the clinic's offerings and enjoy exclusive perks. Guests will receive complimentary B12 or Glutathione shots, access to special discounts on wellness services, and the chance to win wellness-themed raffle prizes. The event promises a fun and energizing introduction to the New Hope Vitality experience.
Modern Wellness Services
New Hope Vitality offers a variety of treatments designed to support energy, recovery, and immune health. These include IV Hydration Therapy for enhanced hydration, NAD+ Therapy for cellular and cognitive function, and Vitamin Infusions and Injections for targeted nutritional support. Red Light Therapy is also available to reduce inflammation and support tissue repair.
Advanced Diagnostic & Mental Wellness Care
For those seeking deeper insights into their health or support for mental well-being, New Hope Vitality provides ExoMind™, an FDA-cleared TMS therapy proven effective for depression and showing promise for PTSD, OCD, ADHD, and other cognitive conditions. The clinic also offers Infrared Thermal Imaging, a non-invasive diagnostic tool used to detect early signs of inflammation and vascular concerns. For added convenience, Mobile IV Therapy services are available throughout Orange County, allowing clients to receive care in the comfort of their own homes or on-site.
Event Details
Location: New Hope Vitality, 1503 S Coast Dr, Suite 313, Costa Mesa, CA 92626
Date: Saturday, June 14, 2025
Time: 10:00 a.m. – 3:00 p.m.
Phone: (223) 223-9355
RSVP: https://link.newhopevitality.com/go-pmusa-semg
About New Hope Vitality
New Hope Vitality, formerly known as Oceans IV Hydration of Costa Mesa, is a modern IV therapy and wellness clinic now reopening under a new name and expanded vision. The clinic offers a comprehensive range of integrative wellness services, including IV hydration, NAD+ therapy, vitamin infusions and injections, red light therapy, infrared thermal imaging, and FDA-cleared ExoMind™ TMS therapy. With its Grand Opening event on June 14, 2025, New Hope Vitality invites the community to experience personalized, science-backed care designed to support energy, immunity, recovery, and long-term wellness—inside and out.
Facebook: facebook.com/profile.php?id=61571506956994
Instagram: instagram.com/oceansiv
Media Contact
Company Name: NewHope Vitality
Contact Person: Freddie Schmidt
Email: Send Email
Phone: 223-223-9355
Address: 1503 S Coast Dr Suite 313
City: Costa Mesa
State: CA
Country: United States
Website: https://newhopevitality.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Health Data Interoperability Market to Hit US$352.13 Billion by 2032 with 22.65% CAGR
According to a recent report by Coherent Market Insights, the global Health Data Interoperability Market is estimated to be valued at USD 84.58 billion in 2025 and is expected to reach USD 352.13 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 22.65% from 2025 to 2032. The strong growth of the market is driven by the rising demand for seamless data exchange among healthcare providers, the pursuit of enhanced patient care, and the growing adoption of electronic health records (EHRs) and other digital health technologies. Global Health Data Interoperability Market Key Takeaways According to Coherent Market Insights (CMI), the global health data operability care market size is projected to grow more than 4.1X, increasing from USD 84.58 Bn in 2025 to USD 352.13 Bn by 2032, at a CAGR of 22.65%. By deployment model, cloud-based segment is expected to account for nearly two-thirds of the global health data interoperability market share in 2025. Based on component, software category is anticipated to generate a market revenue of about USD 45.92 Bn in 2025. By type, electronic health records (EHRs) segment will likely account for more than two-fifths of the global market revenue share by 2025. North America is expected to retain its monopoly in the global market due to increasing adoption of digital health technologies. As per Coherent Market Insights' latest health data interoperability market research, North America will hold nearly 2/5 of the global market share in 2025. Asia Pacific health data interoperability market is estimated to be valued at around USD 25.62 Bn in 2025. Growing Adoption of Electronic Health Records (EHRs) Boosting Market Growth Coherent Market Insights' new health data interoperability market analysis offers insights into prominent factors driving industry growth. Increasing adoption of electronic health records (EHRs) is one key growth driver. In the contemporary world, more and more hospitals and clinics are embracing electronic health records. For instance, as per the National Center for Health Statistics, about 88.2% of office-based physicians in the United States use an EMR/EHR system. High adoption of EHRs is creating an urgent need for seamless data exchange across various healthcare systems. This will drive demand for health data interoperability solutions during the forecast period. High Implementation Cost and Lack of Standardization Limiting Market Growth The future health data interoperability market outlook looks promising. However, lack of universal standards and high implementation costs are expected to restrain market growth to some extent. Different healthcare providers often use disparate EHR systems, making seamless data exchange challenging. Absence of universally accepted interoperability standards across regions can hinder consistent integration and data sharing, negatively affecting the health data interoperability market growth. Implementing interoperable systems requires substantial investments in both infrastructure and software. This deters smaller clinics and healthcare providers, especially across underserved regions, from opting for these systems, thereby reducing the health data interoperability market demand. Purchase Now Up to 25% Discount on This Premium Research Report: Rapid Shift Towards Value-Based Care to Create Lucrative Growth Avenues Growing adoption of value-based care (VBC) models is driving demand for improved patient outcomes and cost efficiency across healthcare systems. This transition necessitates seamless health data interoperability to enable coordinated care as well as real-time data exchange and performance measurement. As a result, the shift towards VBC is unlocking significant growth opportunities for health data interoperability companies. Policies like HITECH Act and EU GDPR mandate interoperability as well as patient access to data. They will also create lucrative growth prospects for health data interoperability solution providers in the coming years. Policies like the HITECH Act and the EU GDPR emphasize interoperability as well as patient access to health data. These regulations are expected to drive demand for health data interoperability solutions, creating lucrative growth opportunities for industry players. Impact of AI on the Health Data Interoperability Market AI is revolutionizing the health data interoperability industry by tackling long-standing challenges like fragmented data and inconsistent data standards. Organizations use machine learning and NLP to automate data mapping, convert unstructured records into structured formats, and streamline EHR integration. AI-driven predictive analytics can forecast data exchange needs, enhance real‑time clinical workflows, and reduce clinical errors. Federated learning frameworks allow AI models to train across multiple organizations without moving sensitive patient data, which improves privacy and fosters collaboration. AI-powered interoperability solutions are gaining immense traction in the modern healthcare ecosystem. This is due to their potential to boost operational efficiency, enable personalized care, reduce costs, and accelerate the transition towards value‑based models. Emerging Health Data Interoperability Market Trends Rising demand for patient-centric care is a key growth-shaping trend in the market. Today, patients want access to their health information through mobile apps and patient portals. This is creating a need for connected systems. Growing popularity of cloud-based interoperability solutions is expected to boost the overall health data interoperability market value. These scalable and cost-effective platforms are gradually replacing on-premise systems across various regions. Rise of telehealth services and adoption of remote patient monitoring devices are also positively impacting the health data interoperability market growth. These technologies require robust interoperability solutions to ensure seamless data flow between patients, healthcare providers, and monitoring platforms. Analyst's View 'The global health data interoperability market is poised to exhibit robust growth, owing to increasing government mandates and regulatory frameworks, widespread adoption of electronic health and medical record systems (EHR/EMR), and a growing emphasis on value-based care models,' said senior analyst Komal Dighe. Current Events and Their Impact on the Health Data Interoperability Market Event Description and Impact U.S. HTI-1 Final Rule Description: U.S. HTI-1 Final Rule enforces FHIR-based standards for certified health IT systems. Impact: This drives adoption of compliant interoperability platforms and APIs, leading to market growth. EU's European Health Data Space (EHDS) Rollout Description: European Union's EHDS initiative, officially implemented in 2025, requires member states to adopt standardized cross-border health data sharing through unified interoperability frameworks. Impact: This is driving health IT vendors to comply with EHDS standards as well as boosting demand for FHIR-based platforms and multilingual data exchange solutions. Competitor Insights Key companies in health data interoperability market report include: - Cerner Corporation - Epic Systems Corporation - Meditech - Allscripts Healthcare Solutions - athenahealth - InterSystems Corporation - Philips Healthcare - GE Healthcare - Oracle Health Sciences - NextGen Healthcare - IBM Watson Health - Microsoft Health - McKesson Corporation - Siemens Healthineers - Infor Healthcare Key Developments In March 2025, 1upHealth sets a new benchmark for health data interoperability with the launch of its new 1up Platform. The new platform, built on a modern lakehouse architecture, is designed to deliver 'Health Data On Demand'. It offers real-time data access, scalable management, and advanced analytics to help healthcare organizations enhance operational efficiency, care quality, and patient outcomes. In March 2025, Epic Systems Corporation unveiled industry-leading Genomics, AI, and interoperability solutions at the HIMSS 2025 Conference. These new solutions are designed to help healthcare organizations advance in rapidly evolving environment. They have the potential to enhance clinical care, streamline operations, and foster more personalized patient treatments. In January 2025, MEDITECH unveiled its new set of APIs fully compatible with version 4 of the United States Core Data for Interoperability (USCDI v4). This new launch highlights the company's leadership in advancing standards-based interoperability across healthcare systems. Market Segmentation Deployment Model Insights Cloud-Based On-Premises Component Insights Hardware Software Services Type Insights Electronic Health Records (EHR) Health Information Exchange (HIE) Interoperability Solutions Integration Platforms Interoperability Level Insights Foundational Interoperability Structural Interoperability Semantic Interoperability End User Insights Healthcare Providers Healthcare Payers Pharmaceutical Companies Research Institutions Regional Insights North America U.S. Canada Latin America Brazil Argentina Mexico Rest of Latin America Europe Germany U.K. Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa § Central Africa Get Customization on this Report: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Media Contact Company Name: Coherent Market Insights Contact Person: Mr. Raj Shah Email: Send Email Phone: +1-252-477-1362 Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States City: Burlingame State: California Country: United States Website:
CTV News
2 hours ago
- CTV News
Long-term disability costs in Sudbury increase by 188% since 2019, audit shows
Tom Davies Square is seen in this file photo. An audit of attendance in departments across Greater Sudbury shows that the cost of long-term disability claims have spiked by 188 per cent since 2019, while the cost of short-term disability is up by 69 per cent in the same period. An audit of attendance in departments across Greater Sudbury shows that the cost of long-term disability claims spiked by 188 per cent since 2019, while the cost of short-term disability is up by 69 per cent in the same period. The city's audit committee asked for the review in December 2023 to give city councillors a better idea of the state of absenteeism. The audit looked at 31 departments at the city with 1,756 employees. 'From 2019 to 2024, STD claim volumes increased by 34 per cent and their duration also increased marginally,' Auditor General Ron Foster wrote in his report. Pioneer Manor Wings Greater Sudbury owns and operates a long-term care home, and LTC homes tend to have higher absentee rates. 'Since 2019, the volume of LTD claims increased by 28 per cent.' Long-term disability claim costs have risen from $3.2 million in 2019 to $9.2 million in 2024. Of those claims, 45 to 60 per cent each year were related to mental health disorders. Disability claims are paid for by Canada Life Insurance, the audit said. Foster's audit, which is headed to the audit committee June 17, focused on departments with the highest average absentee rates. Sudbury paramedics Unlike many single-tier municipalities, Sudbury offers paramedic services that are often the responsibility of regional governments. That included long-term care and transit services, fire and paramedic services, environmental and linear services, asset and fleet, and security and bylaw services. The highest rate was in the community development department, which includes long-term care and transit staff among its 639 employees. The absence rate between 2019 and 2023 was 10.1 per cent, averaging 22 days per employee. Second was the community safety department (including paramedics and firefighters), where the 295 workers had an average absentee rate of 6.9 per cent, or 16 days per worker. One of the issues, the audit said, is that the city doesn't have a corporate-wide policy to manage absenteeism. As a result, different departments manage the problem in different ways, with mixed results. 'This audit recommends developing and implementing an integrated attendance management program to manage attendance across the city,' Foster wrote. GOVA transit GOVA transit is changing its scheduling policies to address high overtime and absentee rates. 'It also recommends a number of revisions to improve the effectiveness of the city's disability management program.' Provides more services than most While absentee rates are generally higher than other cities in Canada, as a single-tier municipality, Greater Sudbury offers services others don't, such as long-term care and paramedicine. Those services tend to have higher absenteeism, somewhat skewing the overall results. Foster said his audit found a connection between high overtime rates and high absenteeism rates, which suggests staffing levels and scheduling policies could be a factor. Another factor was that, unlike other municipalities, Sudbury offered staff six extra paid sick days in 2022 and an extra three in 2023 'to lessen the impact of the COVID-19 pandemic on employees,' the report said. Progress has already been made in some areas, Foster said. For example, he said Pioneer Manor now has a dedicated staffer who monitors attendance and has developed new procedures to manage absenteeism. Environmental services changed its staffing model and 'has addressed overtime effectively.' Foster recommends studying how cities with lower rates approach the issue and adopting best practices. Read the full report here.
Globe and Mail
6 hours ago
- Globe and Mail
PFE's New & Acquired Drugs Hold Key to Revenue Growth Amid Headwinds
With the end of the pandemic, sales of Pfizer 's PFE COVID products, Comirnaty and Paxlovid, have declined. Though COVID revenues are declining, Pfizer's non-COVID operational revenues improved in 2024 and so far in 2025, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen. Year 2023 was a record year for Pfizer in terms of new drug approvals. It received nine new medicine/vaccine approvals in 2023 that have begun to contribute to top-line growth. In 2024, it gained approval for some interesting new products like two gene therapies for hemophilia, Hympavzi (marstacimab) and Beqvez/Durveqtix (fidanacogene elaparvovec). The December 2023 acquisition of Seagen strengthened Pfizer's position in oncology by adding four antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak. The acquired Seagen products contributed meaningfully to Pfizer's revenues in 2024 and the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline. Pfizer faces its share of challenges, including declining sales of its COVID-19 products, U.S. Medicare Part D headwinds, the upcoming loss of exclusivity cliff, uncertainties around tariffs and a volatile macro environment. However, its new products/late-stage pipeline candidates and newly acquired products, including those acquired from Seagen, position it strongly for operational growth in 2025 and beyond. Competition in the Oncology Space Other large players in the oncology space are AstraZeneca AZN, Merck MRK and Bristol-Myers BMY. For AstraZeneca, oncology sales now comprise around 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Merck's key oncology medicines are PD-LI inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for around 50% of Merck's pharmaceutical sales. Bristol-Myers' key cancer drug is PD-LI inhibitor, Opdivo, which accounts for around 20% of its total revenues. PFE's Price Performance, Valuation and Estimates Pfizer's stock has declined 4.4% so far this year compared with an increase of 3.1% for the industry. Image Source: Zacks Investment Research From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 7.97 forward earnings, lower than 15.54 for the industry and the stock's 5-year mean of 10.91. The Zacks Consensus Estimate for 2025 earnings has risen from $2.98 per share to $3.06 per share, while that for 2026 has gone up from $3.00 to $3.09 per share over the past 60 days. Pfizer has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report
